Other Information
−Removed: following exhibits are included as part of this report:
−Removed: Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No.
−Removed: 001-40943) filed with the SEC on November 3, 2021).
−Removed: Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K (File No.
−Removed: 001-40943) filed with the SEC on November 3, 2021).
−Removed: Rule 13a-14(a)/15d-14(a) Certification of Erica L.
−Removed: Rule 13a-14(a)/15d-14(a) Certification of Erica Gates.
−Removed: Certification pursuant to 18 U.S.C.
−Removed: Section 1350 by Chief Executive Officer.
−Removed: Certification pursuant to 18 U.S.C.
−Removed: Section 1350 by Corporate Controller.
−Removed: Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within
−Removed: the Inline XBRL document.
−Removed: XBRL Taxonomy Extension Scheme Document
−Removed: XBRL Taxonomy Extension Calculation Linkbase Document
−Removed: XBRL Taxonomy Extension Labe Linkbase Document
−Removed: XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: XBRL Taxonomy Extension Definition Linkbase Document
−Removed: Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
−Removed: Filed or furnished herewith
−Removed: In accordance with the requiremen ts
−Removed: of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
−Removed: duly authorized.
−Removed: November 30, 2021
−Removed: Executive Officer
+Added: following exhibits are filed herewith or are incorporated by reference to exhibits previously filed with the SEC.
+Added: Amended Settlement Allocation Agreement dated March 31,2022 between the Company and Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, Biofrontera Development GmbH, Biofrontera Neuroscience GmbH, (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on April 5, 2022).
+Added: Certification
+Added: of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002
+Added: Certification
+Added: of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes Oxley Act of 2002
+Added: Inline XBRL Instance Document
+Added: Inline XBRL Taxonomy Extension
+Added: Schema Document
+Added: Inline XBRL Taxonomy Extension
+Added: Calculation Linkbase Document
+Added: Inline XBRL Taxonomy Extension
+Added: Definition Linkbase Document
+Added: Inline XBRL Taxonomy Extension
+Added: Label Linkbase Document
+Added: Inline XBRL Taxonomy Extension
+Added: Presentation Linkbase Document
+Added: Cover Page Interactive
+Added: Data File (embedded within the Inline XBRL document and included in Exhibit 101)
+Added: Filed herewith.
+Added: to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
+Added: behalf by the undersigned thereunto duly authorized .
+Added: BIOFRONTERA INC.
Executive Officer
−Removed: November 30, 2021
−Removed: Accounting Officer)
+Added: Authorized Officer, Principal Executive Officer and Principal Financial Officer )
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.